Advertisement

Pfizer launches dual-chamber syringe for patients with hemophilia

Pfizer Inc. recently launched a syringe that aims to help hemophilia patients lead active lives and take care of their condition faster and easier.

Pfizer Inc. recently launched a syringe that aims to help hemophilia patients lead active lives and take care of their condition faster and easier.

Its new Prefilled Dual-Chamber Syringe to administer Xyntha antihemophilic factor (recombinant) plasma/albumin-free includes the Xyntha powder and the diluents within the syringe. This eliminates the transfer step during reconstitution.

Advertisement

“All you have to do is push one button. In the past, [antihemophilic syringes] were multi-step kits with a syringe, several needles, and 2 vials,” said Marcus Carr, Jr., MD, PhD, FACP, Hematology Disease Area Lead for Pfizer’s Specialty Care Business Unit. The Dual-Chamber Syringe is easier for patients - who typically don’t have full range of motion in one or both arms - and for their caregivers to use, Carr said.

The syringe is used to deliver Xyntha by intravenous infusion after reconstitution of a freeze-dried powder with the diluents (0.9% sodium chloride). The new, prefilled syringe provides 3,000 IU of plasma, the highest dose, in a low, 4 mL volume. Other dosages of Xyntha will be available in the Dual-Chamber Syringe later this year.

Xyntha is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A and for surgical prophylaxis in patients with hemophilia A.


Advertisement
Advertisement